HLA as risk and protection antigens against urinary tract diseases

Abstract. Currently, there is no doubt about the feasibility of determining frequency HLA and analysis genetic associations, including those that determine state immunity, in patients with genitourinary disease.
 The study aimed to evaluate phenotypes most common diseases system identify risk antigens or protectors.
 Methods. distribution was studied 384 pyelonephritis glomerulonephritis 464 urological (chronic cystitis, chronic proliferative prostatitis, prostate sclerosis, prostatic hyperplasia, cancer). HLAs were defined using a standard microlymphocytotoxic test (Terasaki’s test) on Terasakiґs planchette panels anti-HLA serums (20 locus A, 31 – B 9 DR). control group consisted 350 healthy donors from Ukraine.
 frequencies diseased subjects compared taking each antigen separately, χ2 test. value relative disease (RR) determined by coefficient: RR = ab/cd, where number positive for this antigen, b persons control, negative antigen; c d antigen. Indicators RR≥ 2.0 considered significant.
 Absolute (attributive) as an etiological fraction, which formula: s x - y/1 y, patients, y people. indicator s> 0,1 reliable.
 Results. association certain histocompatibility (RR≥2) shown. causal role significant absolute (А10, А11; В14, В16) (A24, А28; B8; DR4, DR52), (including proliferative) (A10, B14, B16), prostatitis autoimmune component impaired fertility) (А24, В8, В52), sclerosis А28), hyperplasia (А29, В38) cancer (А25, А29, В40, В44, В49) has been established. HLA-antigens associated protection against these pathologies have also identified А2, А24, В21, В35 А9, В12, В16, В18 glomerulonephritis; А25, А26, В5, В17 its complications, А10, B15, B17 A1, B5, B13, B15 cancer.
 Conclusion. proves identifying their associations different diseases, allows predicting risks treatment optimization.